The utility of wearable devices in assessing ambulatory impairments of people with multiple sclerosis in free-living conditions

Shaoxiong Sun; Amos A Folarin; Yuezhou Zhang; Nicholas Cummins; Shuo Liu; Callum Stewart; Yatharth Ranjan; Zulqarnain Rashid; Pauline Conde; Petroula Laiou; Heet Sankesara; Gloria Dalla Costa; Letizia Leocani; Per Soelberg Sørensen; Melinda Magyari; Ana Isabel Guerrero; Ana Zabalza; Srinivasan Vairavan; Raquel Bailon; Sara Simblett; Inez Myin-Germeys; Aki Rintala; Til Wykes; Vaibhav A Narayan; Matthew Hotopf; Giancarlo Comi; Richard JB Dobson; RADAR-CNS consortium

arXiv · 2112.11903

The utility of wearable devices in assessing ambulatory impairments of people with multiple sclerosis in free-living conditions

View original source ↗Read source document ↗Export metadata ↓

Abstract

Multiple sclerosis (MS) is a progressive inflammatory and neurodegenerative disease of the central nervous system affecting over 2.5 million people globally. In-clinic six-minute walk test (6MWT) is a widely used objective measure to evaluate the progression of MS. Yet, it has limitations such as the need for a clinical visit and a proper walkway. The widespread use of wearable devices capable of depicting patients activity profiles has the potential to assess the level of MS-induced disability in free-living conditions. In this work, we extracted 96 activity features in different temporal granularities (from minute-level to day-level) and explored their utility in estimating 6MWT scores in a European (Italy, Spain, and Denmark) MS cohort of 337 participants over an average of 10-month duration. We combined these features with participant demographics using three regression models including elastic net, gradient boosted trees and random forest. In addition, we quantified the individual feature contribution using feature importance in these regression models, linear mixed-effects models, generalized estimating equations, and correlation-based feature selection (CFS). The results showed promising estimation performance with R2 of 0.30, which was derived using random forest after CFS. This model was able to distinguish the participants with low disability from those with high disability. Furthermore, we observed that the minute-level (no longer than 8 minutes) step count, particularly those capturing the upper end of the step count distribution, had a stronger association with 6MWT. The use of a walking aid was indicative of ambulatory function measured through 6MWT. This study provides a basis for future investigation into the clinical relevance and utility of wearables in assessing MS progression in free-living conditions.

Explore related subjects

q-bio.QM

Keep this discovery

BibTeX RIS

Shaoxiong Sun, Amos A Folarin, Yuezhou Zhang, Nicholas Cummins, Shuo Liu, Callum Stewart, Yatharth Ranjan, Zulqarnain Rashid, Pauline Conde, Petroula Laiou, Heet Sankesara, Gloria Dalla Costa, Letizia Leocani, Per Soelberg Sørensen, Melinda Magyari, Ana Isabel Guerrero, Ana Zabalza, Srinivasan Vairavan, Raquel Bailon, Sara Simblett, Inez Myin-Germeys, Aki Rintala, Til Wykes, Vaibhav A Narayan, Matthew Hotopf, Giancarlo Comi, Richard JB Dobson, RADAR-CNS consortium. 2021-12-22. The utility of wearable devices in assessing ambulatory impairments of people with multiple sclerosis in free-living conditions. https://arxiv.org/abs/2112.11903

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Many biological discovery problems require experiments to be selected sequentially under constrained budgets. CRISPR screening is a prominent example, as exhaustive perturbation testing is often infeasible and candidate perturbations must instead be prioritized over multiple experimental rounds. Despite the importance of this problem, existing benchmarks for adaptive hit discovery remain limited in scale and diversity. Here, we introduce AssayBench-Loop, a large-scale benchmark for adaptive hit discovery comprising 1,389 CRISPR screens across five phenotype categories. Beyond enabling systematic evaluation, its scale makes it possible to learn acquisition strategies across historical experiments. Building on this resource, we introduce AssayLoop, a sequential experimental design framework combining AssayFormer, a transformer-based amortized acquisition policy trained across historical screens to adapt from experimental feedback, with LLM-derived biological priors through an adaptive handoff. In this view, completed experiments become training data for learning how accumulated evidence should guide what to test next, while LLMs provide prior biological knowledge to seed the search. We further introduce AssayLLM, showing that the same principle can be extended directly to an LLM through task-specific post-training. On temporally held-out screens, AssayLoop achieves a 5.67-fold enrichment over random selection and recovers 27.7% of hits after assaying approximately 5% of the candidate library, outperforming existing adaptive-design methods and standalone LLMs, and AssayFormer alone. Performance improves with increasing historical training data and transfers to phenotype categories excluded from training. These results demonstrate the value of learning acquisition policies across historical experiments and combining them with broad biological priors for efficient adaptive hit discovery.

q-bio.QM↗

arXiv2026

Multi-Task Bacterial Colony Detection and Classification Using YOLOv8 with Edge Optimization for Resource-Constrained Deployment

Manual counting and classification of bacterial colonies are critical yet labor-intensive tasks in microbiology, prone to human error particularly on densely populated plates. This work proposes a multi-task deep learning framework trained on the Annotated Germs for Automated Recognition (AGAR) dataset (18,000 images; 9,202 training / 3,067 testing) to automate Colony Forming Unit (CFU) enumeration and species classification. A custom multi-task CNN employing global regression served as the baseline, but demonstrated limited performance in clustered colony environments due to the absence of spatial localization. To address this, a YOLOv8 object detection architecture was adopted with high-resolution 1024x1024 inputs, enabling instance-level colony detection and label assignment. The model achieved a classification accuracy of 98.13% and a counting accuracy of 98.27% (within a 10-colony margin), demonstrating strong predictive capability. To bridge the gap between model performance and practical deployability, the trained model was optimized through unstructured and structured pruning, ONNX conversion, and reduced-precision inference (FP32, FP16, INT8). On a Raspberry Pi 4B, ONNX FP32 and FP16 variants offered the best balance between inference speed (~6.4s) and accuracy (MAE ~2.20). Unstructured pruning preserved predictive accuracy (MAE ~2.01) without runtime gains, while structured pruning resulted in significant accuracy degradation (MAE ~6.3), revealing the sensitivity of instance-level colony detection to architectural compression. These findings provide practical guidance for selecting optimization strategies in resource-constrained laboratory deployments.

q-bio.QM↗

arXiv2026

ADMET-EvO: a self-evolving scientific agent for sustained research across heterogeneous tasks

Scientific agents can move beyond automated model building by using accumulated evidence to revise both their questions and experimental strategies. The challenge is sustaining this adaptation across heterogeneous tasks without overfitting decisions to internal validation. Absorption, distribution, metabolism, excretion and toxicity (ADMET) prediction provides a demanding setting across diverse assays, datasets and chemical domains. We therefore developed ADMET-EvO, an evidence-gated agent that formalizes endpoints, generates falsifiable hypotheses and tests interventions across data, feature and model axes. It carries supported, rejected and inconclusive outcomes forward to guide each new cycle. Across the 22-task Therapeutics Data Commons (TDC) ADMET benchmark, ADMET-EvO achieved the highest task-normalized score of 96.77. Evidence-guided selection reduced cumulative fitting time by 72.2% within a predefined non-inferiority margin. It also formalized 43 toxicity-related tasks and constructed endpoint-specific predictors. Together, these results show how ADMET-EvO can accumulate evidence, revise its strategy and expand its research scope over time.

q-bio.QM↗